September 12: The Week in Cancer News
Combination of targeted therapy and chemotherapy prolongs survival in lung cancer, and FDA approves a chemotherapy-releasing device to treat bladder cancer.
Progress Against Cancer
Combination of targeted therapy and chemotherapy prolongs survival in lung cancer, and FDA approves a chemotherapy-releasing device to treat bladder cancer.
FDA expands selumetinib approval to include pediatric patients as young as 1 year with inoperable plexiform neurofibromas. The U.S. Food and Drug Administration (FDA) has approved selumetinib (Koselugo) granules and capsules for pediatric patients...
The FDA has approved a delivery system that, once inserted into the bladder, delivers a local dose of the drug gemcitabine. The U.S. Food and Drug Administration (FDA) has approved a gemcitabine intravesical system...
The second AACR Childhood Cancer Predisposition Workshop gathered experts from around the world to refine surveillance strategies, expanding recommendations to nearly 100 syndromes.
New research is redefining the role of surgery, revealing approaches to help cancer patients preserve their organs, function, and identity without compromising outcomes.
Rising prostate cancer rates reignite questions about screening guidelines, and a government report describing the health risks of alcohol may never be published.
New research highlights approaches that could provide better long-term quality of life for childhood cancer survivors into adulthood.
Some people’s cancer treatment may not align with their care goals, and a blood test may detect ovarian cancer at early stages.
For August 2025, the editors of AACR's journals highlighted studies on liquid biopsy for brain cancer, new treatment strategies for prostate and colorectal cancers, and more.
A chemotherapy-releasing device helps destroy bladder cancer tumors, and long-distance running linked to increased risk for precancerous polyps.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More